t i o n p r o h i b i t e d Introduction
Inhaled drugs play an important role in the treatment of asthma and chronic obstructive pulmonary disease (COPD), but their effectiveness and benefit/risk ratios are critically dependent upon delivery to their appropriate targets in the respiratory tract and, ideally, nowhere else. 1 This requires that patients use delivery devices in a manner shown to optimise drug delivery. Otherwise, therapeutic benefit is reduced and the risk of adverse events increased -and both of these outcomes may in turn compromise compliance. 2, 3 The inhalation devices most commonly used are pressurised metered-dose inhalers (pMDIs) and dry-powder inhalers (DPIs). Both deliver a precise amount of drug in the form of aerosol particles of a size suitable for reaching the conducting airways, but only if used properly. Some patients cannot use particular devices because of factors such as age, disability and inadequate lung function. Even when patients can in theory use a particular device, errors of technique, some of which may critically compromise drug delivery, are well known to be frequent. [2] [3] [4] [5] With pMDIs, two of the most critical errors are failure to coordinate inhalation with actuation of the device, 6 and inhaling the aerosol too quickly. 7 With DPIs, successful aerosolisation of the dry powder depends on both the velocity and the acceleration of the inhalation manoevre, which in turn requires rapid and forceful inhalation. 8 Problems are further increased when patients use more than one type of inhaler, resulting in confusion in terms of the different techniques required for each. 9 Although coaching can improve the ability to use inhalers, it has been found that many patients revert to an incorrect inhalation technique within a short period. 4, 10 Thus, regular monitoring of inhalation techniques is necessary. Because the full potential of inhaled drugs cannot be achieved unless patients understand how to properly use inhaler devices, there is a need to train patients more effectively in following a proper sequence of inhalation steps in order to ensure maximum delivery of an inhaled drug to receptor sites in the lungs. Accordingly, there is a need for an inhalation training apparatus which will provide the patent and physician with a 'real-time', interactive representation of the inhalation process. Ideally, an inhalation training apparatus would provide visual feedback representing the actual distribution of inhaled aerosol in the lungs and show with reasonable accuracy the amount of aerosol delivered to the receptor sites. Such feedback would convey a conceptual understanding of the proper inhalation process, and thereby increase the likelihood that the patient would retain the correct technique. To date, various aids have appeared which are designed to help patients use inhalers correctly and efficiently. Some of these provide real-time, interactive sensory feedback of the patient's performance in various critical aspects of inhalation technique, which would seem optimal for "instilling" the correct technique into the patient's subconscious, but many do not.
In this article we review the tools for training patients in the correct use of both pMDIs and DPIs.
Training tools 1. "2Tone" Metered-Dose Inhaler Training Device
The "2Tone" Metered-Dose Inhaler Training Device, or "2Tone" Trainer, (Canday Medical Ltd, Newmarket, UK) is a training aid to help patients inhale aerosolised particles from pMDIs at a rate optimal for airways deposition. Most untrained patients inhale far too quickly from a pMDI and this is one error of pMDI technique which can critically reduce drug delivery. 7 The training device looks similar to a pMDI but contains no medication or propellant (see Figure 1) . All of the components are manufactured from medical grade plastics; it has been designed as a "single patient use" device for hygienic reasons, and should be cleaned at least once a month. The device is available in several European countries as well as in the USA. The patient information leaflet provided with this training aid encourages patients to practice using the device in the same way that they would use their pMDI. During use, the "2Tone" mimics what it is like to inhale through a pMDI and provides audible feedback on how fast air is being inhaled. 7 A pair of sensitive reeds vibrate when air flows through them above a certain pre-determined speed, producing a single tone with optimal inhalation rates (30-60 l/min), two tones if the rate is too fast (>60 l/min), and no noise at all if it is too slow. Patients are advised to obtain the onetone noise and thus become accustomed to the degree of inspiratory effort they need to make to achieve this rate through a pMDI. Compared with verbal training, the "2Tone" has been shown to produce sustained improvement in inhalation technique, lung function and quality of life in asthmatics using pMDIs, presumably because of better deposition of drug within the airways. 7 Furthermore, improvements in asthma quality of life and lung function were obtained without changing the dose and without having to retrain the technique. 7 These findings highlight the potential of the "2Tone" to decrease costs as well as to improve health-care outcomes.
Turbutest
The Turbutest (Figure 2 ) is used to train patients in the correct use of the Turbohaler device. This device, available in several European countries, is a replica connected to an electronic sensor that measures peak inspiratory flow (PIF). 11 The Turbutest grades PIF visually (3 lights >60 l/min, 2 lights 40-60 l/min, 1 light 30-40 l/min, and no lights <30 l/min). According to the manufacturer's specifications, patients must be able to light at least 2 lights in order to be able to generate a PIF sufficient to aerosolise the dry powder into particles of respirable size when using a Turbohaler. Inadequate PIF is one of the errors in DPI technique which may critically reduce drug delivery. In addition, the Turbutest also evaluates whether or not the patient has correctly performed the initial rotation of the base of the Turbohaler required to prime the inhaler; this is also a frequent and critical error in Turbohaler use. 5 In a large (n=600) group of adult asthmatic patients, the Turbutest device revealed that 33% of them generated inadequate PIF when using the Turbohaler, although none reported difficulty in using it beforehand. 
In-CheckDial
The In-CheckDial (Clement Clarke International Ltd, UK; see Figure 3 ) is a hand-held inspiratory airflow meter designed to identify the most appropriate inhaler device for patients, based on their ability to learn and achieve an optimal flow rate. [12] [13] [14] [15] It accurately simulates the resistance encountered when using a number of different inhalers currently on the market, and measures the inspiratory flow rate achieved by the patient. Although designed primarily for DPIs, it can also measure inspiratory flow through an inhaler with no resistance such as a pMDI, with or without a spacer, or a breath-actuated pMDI. The In-CheckDial is composed of two parts: an inspiratory flow meter and a rotating dial that selects different resistances ( Figure 4 ). It is supplied with a sterilisable mouthpiece and a card showing optimal flow ranges for various devices. Patients unable to achieve a flow rate within the optimal range for a given inhaler should be provided with an alternative device. As mentioned, both the speed and the acceleration of the inspiratory manouevre when using a DPI critically affect the respirable dose. 8, 16 Although the In-CheckDial does not measure the speed of inhalation, Broeders and colleagues have shown that it correlates with PIF when patients use DPIs.
14 In one study, 12 the In-CheckDial showed that only a minority of COPD patients could generate a PIF of 60 l/min which is reported to be the minimum desirable flow rate when using the Turbohaler DPI. 17 This finding is of importance since in vitro studies with the Turbohaler device 18, 19 have highlighted the high variability of the emitted dose below this inhalation rate. Although some clinical response may be obtained at inhalation rates between 30 and 60 l/min through the Turbohaler device, 20 the response might be variable and in some cases slight. In another study, 21 the InCheckDial detected that 14 out of 74 COPD patients (19%) were not able to generate even the minimum (30 l/min) inhalation rate reported to be required for use of the Turbohaler device. Similarly, in a group of young children apparently experienced with use of the Turbohaler device, the In-CheckDial revealed adequate PIF (>60 l/min) in only 68%. 15 In summary, the InCheckDial is a powerful tool that can greatly aid healthcare providers when prescribing inhalers for the first time and when checking technique. It provides real-time, objective feedback to patients and may improve drug delivery and compliance. [12] [13] [14] [15] It can be used to check PIF in patients of all ages when using DPIs, whether new to the device or not.
Mag-Flo inhaler flow indicator
The Mag-Flo inhaler flow indicator (Fyne Dynamics Ltd, UK) evaluates patients' ability to use a variety of DPIs including the Turbohaler, the Diskus/Accuhaler, the Handihaler and the Novolizer devices. 22 This inhalation aid ( Figure 5 ) uses a magnetic flow sensor attached by an adaptor to the inhaler or training placebo. 22 When the patient inhales correctly, the magnetic flow sensor is activated, switching on a battery powered green light, providing visual, real-time feedback to the patient as to inhalation speed. 22 As far as we are aware, no published studies have evaluated the accuracy of this device in flow detection as well as its effect on patients' inhalation technique. However, it has the potential to teach patients using DPIs to inhale at an appropriate rate and pick out those who cannot.
Aerosol Inhalation Monitor
The Aerosol Inhalation Monitor (Vitalograph Ltd, Buckingham, UK) is an electronic, desktop pMDI trainer that measures patients' inspiratory flow rate and monitors coordination of inhalation with pressing the pMDI canister ( Figure 6 ). It includes a placebo pMDI with a sensitive flowhead which detects flow once the patient starts inhaling. Feedback to the user is in the form of different coloured lights and an analogue needle gauge which indicates inspiratory flow rate, including a desired flow range. 23 During practice, the patient is asked to keep the needle gauge within the desired flow range. After completion of the full manouevre the device displays three coloured lights labelled "firing", "delivery" and "breath hold". A green light indicates that the patient performed the corresponding aspect of the inhalation correctly. Conversely, a red light indicates an incorrect technique. A secondary optional display provides an incentive device utilising several lights overlain with cartoon figures. 23 Thus, the Aerosol Inhalation Monitor provides health educators and patients with both a visual and a quantitative assessment of patients' inhalation technique wih pMDIs. 23 Furthermore, the device has been used in patients with acute asthma to verify correct inhalation technique and as a teaching aid with variable success. 24 The Aerosol Inhalation Monitor has some disadvantages: feedback is not fully interactive and is not displayed across the entire time course of the manoevre, and performance parameters are not operator programmable.
Inhalation Manager
The Inhalation Manager is a user-friendly, computer-based measuring instrument which enables testing of the inhalatory capacity of patients using Turbohaler or Diskus/Accuhaler DPI devices and the Autohaler breath-actuated pMDI. It assesses the entire inspiratory manouevre and thus provides feedback to the patient and the health professional. In one study, 25 the Inhalation Manager detected substandard inhalation technique in 1.5%, 16.7% and 38.9% of adult patients up to 60 years old using the Autohaler, Diskus/Accuhaler and Turbohaler, respectively, rising to 1.5%, 31.5% and 66.1% in those aged over 60 years old. The Inhalation Manager also offers prediction of mass output and particle size distribution from any individual inspiratory manouevre through each of these inhaler devices, based on measurements from compatible flow profiles measured in the laboratory. 8 Thus, the device offers the opportunity to hone inhaler technique precisely in individual patients at least with the currently covered devices. 
SmartMist
The SmartMist Respiratory Management System (Aradigm Corporation; Hayward, CA, US), is a hand-held breath-actuated, microprocessor-controlled, accessory for use with pMDIs. This electronic device, available in the USA, allows physicians to evaluate objectively patient adherence to treatment by recording the date and time of medication use. [26] [27] [28] [29] In addition to serving as a reporting tool for compliance, the SmartMist records the inspiratory flow rate and the 'inspiratory firing volume' (the volume of air inhaled prior to actuation of the aerosol generation) at the time of delivery. Therefore, it can be used for assessing patients' inhalation technique, and, consequently, for training. The device prompts the patients to hold their breath for 10 seconds post-inhalation for optimum deposition. Furthermore, the electronic peak flow meter in the device can be used to assess and record the patient's response to therapy. 29 The SmartMist (Figure 7) consists of a larger device that accommodates the pMDI and actuator with only the mouthpiece exposed. It contains a microprocessor that analyses an inspiratory profile and automatically actuates the pMDI when predefined conditions of inspiratory flow rate (25 to 60 L/min) and inspired volume (250 to 500 mL) coincide, in order to minimise error in inhalation technique. 29 It provides immediate guidance on technique with a flashing red light when inspiration is too rapid (> 60 L/min), a solid green light when the inspiratory flow is appropriate (25 to 60 L/min), or no light indicating insufficient inspiratory flow (<25 L/min). Using red and green indicator lights to provide instant feedback on proper inhalation technique, the SmartMist guides patients to breathe slowly and evenly, and automatically dispenses drug when the desired flow rate is established. Information on inhalation technique and records data on drug administration can be downloaded with the accompanying cable onto a personal computer. The data can be viewed and printed as a list of events or a series of graphs. The validity and reliability of the SmartMist have been well characterised, 30 and clinical studies performed in asthma patients have shown that the SmartMist improves inhalation technique and diary accuracy for both medication use and pulmonary function values.
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Multimedia training tools
Recorded materials (videotape and digital media such as DVDs) and web-based mutimedia information systems incorporating video clips showing demonstration of correct use of pMDIs and DPIs 32-34 are frequently used for training patients. These information systems offer an attractive alternative option for teaching or reinforcing correct inhaler use, particularly for children and other people who cannot read the information in the manufacturer's patient information leaflet. Multimedia educational software delivers information to a laptop or desktop computer screen using a range of visual and auditory forms, including animation, video, voice-over, and sound effect. The interactive capabilities of such programs and their potential to store users' responses can be harnessed to provide personalised information in engaging forms such as games or quizzes. In addition, using multimedia to deliver health information has practical advantages: electronic information stored on portable disk, computer disk or on a Web page is easy to share across health care settings, and takes up much less shelf space than paper-based methods. Recently, the Aerosol Management Improvement Team (ADMIT) provided its web platform 34 with interactive tools on how to use the most popular inhalation devices throughout the world correctly. Using multimedia may also be more effective than print-based information, as the need for some active input from the recipient is claimed to make learning both easier and more enjoyable than with conventional methods. 35 A degree of choice can be offered as to how information is presented (e.g. language, age, gender, ethnicity). This could increase the acceptability and personal relevance of the information, and help inhaler users to feel more involved in their own health care. Savage and Goodyer 36 compared, in asthma patients, the effects of brief exposure to standard information on correct pMDI use, given by the manufacturer's patient information leaflet and by a multimedia program. They found that both information methods induced similar improvements in global inhaler technique ratings in around a third of patients. There were differences between the two information-giving methods in terms of engaging attention, and in the observed changes in specific aspects of technique. However, unlike paper leaflets, the information provided by multimedia takes up little space, is easy to share, and the technology required is well established and relatively low cost. 
Conclusion
Most professionals would accept that no inhaled drug can effectively treat asthma or COPD unless it reaches the airways, so that using delivery devices to achieve this with maximum efficiency is the cornerstone of management of these diseases. Although guidelines acknowledge that inhalers should be prescribed only after patients have been trained to use them properly and have demonstrated this ability, 37, 38 many studies 4, 5 suggest that this critical aspect of patient care is poorly addressed. Yet health professionals now have a number of tools available with which to hone perfect inhaler technique in each individual patient. Incorrect or inefficient inhaler usage may be a direct consequence of poor instruction, 39 but this is improved (albeit temporarily) by training. 40, 41 The quality of this training is of paramount importance. The manufacturer's instruction sheet alone is ineffective in achieving correct technique. [42] [43] [44] Patients with asthma or COPD using an inhaler for the first time are more likely to demonstrate the correct technique after receiving verbal instruction than after reading the manufacturer's leaflet. 44 Instruction provided in groups or by video can also be as effective as one-to-one instruction in improving technique. 45 As we have stressed in this article, there is now abundant scope for excellent practical instruction with various aids. Inhaler technique education is best delivered by verbal instructions and physical demonstration of the technique by a skilled educator, either face to face or by video. 46, 47 Demonstrating the steps can also help overcome language barriers. 48 What is still missing perhaps is the required time and organisation. Inhaler technique must be rechecked and education must be reinforced regularly in order to maintain correct technique, since inhaler technique deteriorates again after education. 4, 5 Surveys continue to suggest, however, that substantial proportions of patients prescribed inhalers receive no verbal instruction at all, 43, 49 or a brief, one-off session. 50 Follow-up is important when one considers that as early as three days after successful instruction, more than a third of patients may no longer use their DPI correctly, 43 but they fare much better with repetition. 51 Finally, "going through the motions" of inhaler training, even if repeated, although essential is not always enough. The health professional must "go the extra mile" to perfect inhaler technique and eliminate critical errors that can vastly reduce inhaler performance. Training devices to facilitate this are easy to use and in some cases measure patients' inspiratory flow, so that good technique can be learned quickly, even by children, and checked objectively.
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